​
​

VBI Vaccines (VBIV) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

VBI Vaccines Revenue Highlights

Latest Revenue (Y)

$8.68M

Latest Revenue (Q)

$1.21M

Main Segment (Y)

Product

Main Geography (Y)

China Hong Kong

VBI Vaccines Revenue by Period

VBI Vaccines Revenue by Year

DateRevenueChange
2023-12-31-702.40%
2022-12-31-71.47%
2021-12-31--40.53%
2020-12-31--52.23%
2019-12-31--33.80%
2018-12-31-287.86%
2017-12-31-57.85%
2016-12-31--42.62%
2015-12-31-100.00%
2014-03-31-100.00%
2013-03-31-100.00%
2012-03-31-100.00%
2011-03-31-100.00%
2010-03-31-100.00%
2009-03-31-100.00%
2008-03-31-100.00%
2007-03-31-100.00%
2006-03-31-100.00%
2005-03-31--100.00%
2004-03-31--83.94%
2003-03-31--2.86%
2002-03-31-80614.29%
2001-03-31--100.00%
2000-03-31-3.89%
1999-03-31--5.93%
1998-03-31--2.79%
1997-03-31--

VBI Vaccines generated $8.68M in revenue during NA 2023, up 702.40% compared to the previous quarter, and up 258.78% compared to the same period a year ago.

VBI Vaccines Revenue by Quarter

DateRevenueChange
2024-03-31-42.32%
2023-12-31--87.12%
2023-09-30-820.00%
2023-06-30-48.45%
2023-03-31-65.53%
2022-12-31--7.57%
2022-09-30--8.38%
2022-06-30-174.60%
2022-03-31-55.56%
2021-12-31--24.30%
2021-09-30--24.65%
2021-06-30--52.82%
2021-03-31-83.54%
2020-12-31--44.97%
2020-09-30-61.96%
2020-06-30--55.66%
2020-03-31--27.70%
2019-12-31--11.28%
2019-09-30-1.09%
2019-06-30-77.78%
2019-03-31--86.59%
2018-12-31-936.29%
2018-09-30-10.68%
2018-06-30-31.46%
2018-03-31--11.44%
2017-12-31-4.15%
2017-09-30--43.90%
2017-06-30-170.87%
2017-03-31--7.30%
2016-12-31--51.25%
2016-09-30-242.68%
2016-06-30-70.83%
2016-03-31--580.00%
2015-12-31--109.62%
2015-09-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31-100.00%
2013-12-31-100.00%
2013-09-30-100.00%
2013-06-30-100.00%
2013-03-31-100.00%
2012-12-31-100.00%
2012-09-30-100.00%
2012-06-30-100.00%
2012-03-31-100.00%
2011-12-31-100.00%
2011-09-30-100.00%
2011-06-30-100.00%
2011-03-31-100.00%
2010-12-31-100.00%
2010-09-30-100.00%
2010-06-30-100.00%
2010-03-31-100.00%
2009-12-31-100.00%
2009-09-30-100.00%
2009-06-30-100.00%
2009-03-31-100.00%
2008-12-31-100.00%
2008-09-30-100.00%
2008-06-30-100.00%
2008-03-31--

VBI Vaccines generated $1.21M in revenue during Q1 2024, up 42.32% compared to the previous quarter, and up 414.33% compared to the same period a year ago.

VBI Vaccines Revenue Breakdown

VBI Vaccines Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Service-----
Product-----
License-----
R&D Services Revenue-----
Product Revenue-----
R&D Service Revenue-----

VBI Vaccines's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (62.24%), Service (19.87%), and License (17.89%).

Quarterly Revenue by Product

Product/ServiceMar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
Service--------------------
Product--------------------
License--------------------
Product Revenues--------------------
R&D Service Revenues--------------------
R&D Service Revenue--------------------
Product Revenue--------------------

VBI Vaccines's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (48.94%), Service (28.80%), and License (22.27%).

VBI Vaccines Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21Dec 20Dec 19
ISRAEL-----
UNITED STATES-----
China Hong Kong-----
Europe-----
China / Hong Kong-----
Israel-----
China/Hong Kong-----

VBI Vaccines's latest annual revenue breakdown by geography, as of Dec 23: China Hong Kong (64.33%), UNITED STATES (21.25%), Europe (12.50%), and ISRAEL (1.92%).

Quarterly Revenue by Country

CountryMar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
China and Hong Kong--------------------
UNITED STATES--------------------
ISRAEL--------------------
Europe--------------------
China Hong Kong--------------------
China / Hong Kong--------------------
CANADA--------------------
CHINA--------------------
Israel--------------------
China/Hong Kong--------------------

VBI Vaccines's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (79.16%), Europe (16.56%), China and Hong Kong (2.64%), and ISRAEL (1.65%).

VBI Vaccines Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ONTXTraws Pharma--
AUPHAurinia Pharmaceuticals--
ARDXArdelyx--
GRTSGritstone bio--
JAGXJaguar Health--
BBIOBridgeBio Pharma--
VBIVVBI Vaccines--
TNXPTonix Pharmaceuticals--
VXRTVaxart--
OCGNOcugen--
ANIXAnixa Biosciences--
ALLOAllogene Therapeutics--
GOVXGeoVax Labs--
ANVSAnnovis Bio--
AKROAkero Therapeutics--

VBIV Revenue FAQ

What is VBI Vaccines’s yearly revenue?

VBI Vaccines's yearly revenue for 2023 was $8.68M, representing an increase of 702.40% compared to 2022. The company's yearly revenue for 2022 was $1.08M, representing an increase of 71.47% compared to 2021. VBIV's yearly revenue for 2021 was $631K, representing a decrease of -40.53% compared to 2020.

What is VBI Vaccines’s quarterly revenue?

VBI Vaccines's quarterly revenue for Q1 2024 was $1.21M, a 42.32% increase from the previous quarter (Q4 2023), and a 150.31% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $853K, a -87.12% decrease from the previous quarter (Q3 2023), and a 191.13% increase year-over-year (Q4 2022). VBIV's quarterly revenue for Q3 2023 was $6.62M, a 820.00% increase from the previous quarter (Q2 2023), and a 1989.59% increase year-over-year (Q3 2022).

What is VBI Vaccines’s revenue growth rate?

VBI Vaccines's revenue growth rate for the last 3 years (2021-2023) was 1275.91%, and for the last 5 years (2019-2023) was 290.90%.

What are VBI Vaccines’s revenue streams?

VBI Vaccines's revenue streams in c 23 are Service, Product, and License. Service generated $3.99M in revenue, accounting 19.87% of the company's total revenue, up 2543.71% year-over-year. Product generated $12.51M in revenue, accounting 62.24% of the company's total revenue, up 1243.39% year-over-year. License generated $3.6M in revenue, accounting 17.89% of the company's total revenue

What is VBI Vaccines’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of VBI Vaccines was Product. This segment made a revenue of $12.51M, representing 62.24% of the company's total revenue.